Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Targeted Therapies/Targetable Molecules for Treatment of Cancer and Diseases That...
share announcement

Targeted Therapies/Targetable Molecules for Treatment of Cancer and Diseases That Could Predispose to Cancer

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 7775

Special Issue Editors

Dr. Prema Robinson

E-Mail Website
Guest Editor
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: Substance P; Stat3; cancer; tumor; antitumor
Dr. Miguel Muñoz

E-Mail Website
Guest Editor
1. Pediatric Intensive Care United, Virgen del Rocio University Hospital, 41013 Seville, Spain
2. Research Laboratory on Neuropeptides (IBIS), Virgen del Rocio University Hospital, 41013 Seville, Spain
Interests: substance P; neurokinin-1 receptor; neurokinin-1 receptor antagonist; cancer; metastasis; angiogenesis; antitumor
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue will highlight target therapies and targetable molecules that could be availed for treatment of Cancer and Diseases that Predispose to Cancer.

The predominant features of cancer include dysregulated cellular proliferation, cell death, immunosuppressive factors, anti-cancer immune responses and angiogenesis leading to growth, invasion and metastases. Diseases that could predispose to cancer include but are not limited to Lynch syndrome, Li-Fraumeni syndrome, human papillomavirus (HPV) infection, Epstein-Barr virus (EBV) infection, Helicobacter pylori infection, Opisthorchis viverrini infection, Schistosomiasis, chronic diabetes, pancreatitis, ulcerative colitis and Crohn’s disease.

Targeted cancer therapies/targetable molecules include but not limited to hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery molecules.

Targetable molecules include but not limited to transcription factors, signal transduction molecules, peptides, kinases, epigenetic regulatory proteins, DNA damage repair enzymes, and proteasomes.

Dr. Prema Robinson
Dr. Miguel Muñoz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • therapeutic cancer target
  • targetable molecules
  • hormone therapies
  • peptides
  • apoptosis inducers
  • antimetastatic
  • antiangiogenic
  • immunotherapies and toxin delivery molecules

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 3452 KiB  
Article
Therapeutic Potential of a Small-Molecule STAT3 Inhibitor in a Mouse Model of Colitis
by Prema Robinson, Kelsey Montoya, Emily Magness, Emma Rodriguez, Viviana Villalobos, Nikita Engineer, Peng Yang, Uddalak Bharadwaj, Thomas Kris Eckols and David John Tweardy
Cancers 2023, 15(11), 2977; https://doi.org/10.3390/cancers15112977 - 30 May 2023
Cited by 1 | Viewed by 1558
Abstract
Background and Aims: Inflammatory bowel disease (IBD) predisposes to colorectal cancer (CRC). In the current studies, we used the dextran sodium sulfate (DSS) murine model of colitis, which is widely used in preclinical studies, to determine the contribution of STAT3 to IBD. STAT3 [...] Read more.
Background and Aims: Inflammatory bowel disease (IBD) predisposes to colorectal cancer (CRC). In the current studies, we used the dextran sodium sulfate (DSS) murine model of colitis, which is widely used in preclinical studies, to determine the contribution of STAT3 to IBD. STAT3 has two isoforms: (STAT3 α; which has pro-inflammatory and anti-apoptotic functions, and STAT3β; which attenuates the effects of STAT3α). In the current study, we determined the contribution of STAT3 to IBD across all tissues by examining DSS-induced colitis in mice that express only STAT3α and in mice treated with TTI-101, a direct small-molecule inhibitor of both isoforms of STAT3. Methods: We examined mortality, weight loss, rectal bleeding, diarrhea, colon shortening, apoptosis of colonic CD4+ T-cells, and colon infiltration with IL-17-producing cells following 7-day administration of DSS (5%) to transgenic STAT3α knock-in (STAT3β-deficient; ΔβΔβ) mice and wild-type (WT) littermate cage control mice. We also examined the effect of TTI-101 on these endpoints in DSS-induced colitis in WT mice. Results: Each of the clinical manifestations of DSS-induced colitis examined was exacerbated in ΔβΔβ transgenic versus cage-control WT mice. Importantly, TTI-101 treatment of DSS-administered WT mice led to complete attenuation of each of the clinical manifestations and also led to increased apoptosis of colonic CD4+ T cells, reduced colon infiltration with IL-17-producing cells, and down-modulation of colon mRNA levels of STAT3-upregulated genes involved in inflammation, apoptosis resistance, and colorectal cancer metastases. Conclusions: Thus, small-molecule targeting of STAT3 may be of benefit in treating IBD and preventing IBD-associated colorectal cancer. Full article
(This article belongs to the Special Issue Targeted Therapies/Targetable Molecules for Treatment of Cancer and Diseases That Could Predispose to Cancer)
►▼ Show Figures

Figure 1

16 pages, 13879 KiB  
Article
The Role of a Natural Amphibian Skin-Based Peptide, Ranatensin, in Pancreatic Cancers Expressing Dopamine D2 Receptors
by Anna K. Laskowska, Mateusz Szudzik, Aneta Ścieżyńska, Michał Komorowski, Edina Szűcs, Dávid Gombos, Bartłomiej Bączek, Jowita Lipka-Miciuk, Sandor Benyhe and Patrycja Kleczkowska
Cancers 2022, 14(22), 5535; https://doi.org/10.3390/cancers14225535 - 10 Nov 2022
Cited by 5 | Viewed by 1387
Abstract
Despite the progress in early diagnostic and available treatments, pancreatic cancer remains one of the deadliest cancers. Therefore, there is an urgent need for novel anticancer agents with a good safety profile, particularly in terms of possible side-effects. Recently dopaminergic receptors have been [...] Read more.
Despite the progress in early diagnostic and available treatments, pancreatic cancer remains one of the deadliest cancers. Therefore, there is an urgent need for novel anticancer agents with a good safety profile, particularly in terms of possible side-effects. Recently dopaminergic receptors have been widely studied as they were proven to play an important role in cancer progression. Although various synthetic compounds are known for their interactions with the dopaminergic system, peptides have recently made a great comeback. This is because peptides are relatively safe, easy to correct in terms of the improvement of their physicochemical and biological properties, and easy to predict. This paper aims to evaluate the anticancer activity of a naturally existing peptide—ranatensin, toward three different pancreatic cancer cell lines. Additionally, since there is no sufficient information confirming the exact character of the interaction between ranatensin and dopaminergic receptors, we provide, for the first time, binding properties of the compound to such receptors. Full article
(This article belongs to the Special Issue Targeted Therapies/Targetable Molecules for Treatment of Cancer and Diseases That Could Predispose to Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

36 pages, 1814 KiB  
Review
Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy
by María José Bravo, Antonio Manuel Burgos-Molina, Marilina García-Aranda, Maximino Redondo and Teresa Téllez
Cancers 2023, 15(23), 5499; https://doi.org/10.3390/cancers15235499 - 21 Nov 2023
Viewed by 996
Abstract
Cancer is one of the world’s most significant health problems today. Currently, breast cancer has globally surpassed lung cancer as the most commonly diagnosed cancer in women. In 2020, an estimated 2,261,419 new cases were diagnosed in women worldwide. Therefore, there is a [...] Read more.
Cancer is one of the world’s most significant health problems today. Currently, breast cancer has globally surpassed lung cancer as the most commonly diagnosed cancer in women. In 2020, an estimated 2,261,419 new cases were diagnosed in women worldwide. Therefore, there is a need to understand the processes that can help us better treat this disease. In recent years, research in the fight against cancer has often been based on two treatment modalities. One of them is the use of protein kinase inhibitors, which have been instrumental in the development of new therapeutic strategies. Another crucial route is the use of immunotherapy, which has been touted as a great promise for cancer treatment. Protein kinase alterations can interfere with the effectiveness of other treatments, such as immunotherapy. In this review, we will analyze the role played by protein kinase alterations in breast cancer and their possible impact on the effectiveness of the response to immunotherapy treatments. Full article
(This article belongs to the Special Issue Targeted Therapies/Targetable Molecules for Treatment of Cancer and Diseases That Could Predispose to Cancer)
►▼ Show Figures

Figure 1

38 pages, 4098 KiB  
Review
The Galaninergic System: A Target for Cancer Treatment
by Manuel Lisardo Sánchez and Rafael Coveñas
Cancers 2022, 14(15), 3755; https://doi.org/10.3390/cancers14153755 - 01 Aug 2022
Cited by 15 | Viewed by 3212
Abstract
The aim of this review is to show the involvement of the galaninergic system in neuroendocrine (phaeochromocytomas, insulinomas, neuroblastic tumors, pituitary tumors, small-cell lung cancer) and non-neuroendocrine (gastric cancer, colorectal cancer, head and neck squamous cell carcinoma, glioma) tumors. The galaninergic system is [...] Read more.
The aim of this review is to show the involvement of the galaninergic system in neuroendocrine (phaeochromocytomas, insulinomas, neuroblastic tumors, pituitary tumors, small-cell lung cancer) and non-neuroendocrine (gastric cancer, colorectal cancer, head and neck squamous cell carcinoma, glioma) tumors. The galaninergic system is involved in tumorigenesis, invasion/migration of tumor cells and angiogenesis, and this system has been correlated with tumor size/stage/subtypes, metastasis and recurrence rate. In the galaninergic system, epigenetic mechanisms have been related with carcinogenesis and recurrence rate. Galanin (GAL) exerts both proliferative and antiproliferative actions in tumor cells. GAL receptors (GALRs) mediate different signal transduction pathways and actions, depending on the particular G protein involved and the tumor cell type. In general, the activation of GAL1R promoted an antiproliferative effect, whereas the activation of GAL2R induced antiproliferative or proliferative actions. GALRs could be used in certain tumors as therapeutic targets and diagnostic markers for treatment, prognosis and surgical outcome. The current data show the importance of the galaninergic system in the development of certain tumors and suggest future potential clinical antitumor applications using GAL agonists or antagonists. Full article
(This article belongs to the Special Issue Targeted Therapies/Targetable Molecules for Treatment of Cancer and Diseases That Could Predispose to Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop